FDA approves expanded indication for PCSK9 siRNA for primary prevention

News - July 11, 2023

The US Food and Drug Administration (FDA) has approved a label update for inclisiran to include treatment of patients with elevated LDL-c who have an increased risk of heart disease, in addition to diet and statin therapy, for primary prevention of CV events.

Inclisiran was approved by the FDA in December 2021 to lower LDL-c in patients with atherosclerotic CVD and heterozygous FH.

Source: press release Novartis, July 10, 2023

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free